Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038804 · ClinicalTrials.gov registry record · Phase 2
A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT01038804 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 101 participants.
The verdict
NCT01038804, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel as first-line treatment in subjects with human epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.
Interventions
- DRUG Docetaxel
- DRUG YM155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01038804
The ClinicalTrials.gov registry entry for NCT01038804 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01038804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01038804 about?
NCT01038804 is a clinical study titled "A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer". The purpose of this study is to evaluate survival, response rate, safety and tolerability of YM155 given in combination with docetaxel as first-line treatment in subjects with human epidermal growth factor 2 non-overexpressing (HER2 negative) metastatic breast cancer.
What is the current status of trial NCT01038804?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2009-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01038804?
The interventions under investigation include: Docetaxel (DRUG), YM155 (DRUG).
Who is sponsoring clinical trial NCT01038804?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.